Besides this approval, other therapeutic options could be considered, since it was demonstrated that the inhibition of heat-shock protein 90 (HSP90) is an alternative to direct FGFR-kinase inhibition in FGFR2-fusion-driven cancers. This evidence concerns the gene FGFR2 and cancer.